u/discount_math_dm

This matches the trial data.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

the non-peptide is whether this actually works long-term

Not convinced. The evidence does not support that reading.

Mechanistically the bit that matters is Mounjaro. It explains most of the early profile and a decent chunk of the outcome.

Is that on Mounjaro pens or research tirzepatide?

confirmations are confirmations, the exchange rate at 18 blocks is the deal

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

Stablecoin or other?

Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.

sponsor and disclosure questions are always answered publicly

Did you check confirmation speed on that chain?

the appetite change on tirz is more than just reduced hunger, it is different machinery

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Hard agree. The food noise disappears differently on the two compounds.

Tried both. Sema worked, tirz worked better for me, but my injection-site soreness profile was worse on tirz.

TRIUMPH data is phase 2, not phase 3, smaller n and shorter

the absorption problem is solved by non-peptide structure

Strongly agree. Tirz is better than sema is not a claim without a comparator dose.

dual agonism is GIP, do not generalise from semaglutide

This is correct. ATTAIN data is phase 21.